Reoperation does not provide a survival advantage in patients with recurrent Glioblastoma treated with irinotecan/bevacizumab treatment
Ozlem Nuray Sever1, Kadir Oktay2, Ebru Güzel3, Vildan Kaya4, Aslan Güzel2, Mustafa Yıldırım5
1 Department of Internal Medicine and Medical Oncology, Gaziantep University School of Medicine, Gaziantep, Turkey
2 Department of Neurosurgery, Medicalpark Gaziantep Hospital, Gaziantep, Turkey
3 Department of Radiology, Medicalpark Gaziantep Hospital, Gaziantep, Turkey
4 Department of Radiation Oncology, Medstar Antalya Hospital, Antalya, Turkey
5 Department of Medical Oncology, Medicalpark Gaziantep Hospital, Gaziantep, Turkey
Background: Treatment options for recurrent glioblastoma (GBM) have limited efficacy. Although reoperation is useful for both the confirmation of the diagnosis of recurring disease and the relief of the symptoms, its effect on survival is unknown. The aim of this study was to evaulate the impact of second surgery in recurrent GBM.
Methods: Patients with GBM followed in our center between January 2015 and April 2018 were analyzed retrospectively based on the treatment options.
Results: 25 patients diagnosed with recurrent GBM were analyzed. Ten patients (40%) were treated with chemotherapy following reoperation, and 15 patients (60%) were treated with only chemotherapy. No benefits of reoperation were observed in the univariate analysis.
Conclusion: The second surgery in recurrent GBM has limited effect in clinical course.
Ozlem Nuray Sever,
Department of Internal Medicine and Medical Oncology, Gaziantep University School of Medicine, Gaziantep
Source of Support: None, Conflict of Interest: None